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Abstract
Heart disease remains a leading cause of mortality and a major
worldwide healthcare burden. Recent advances in stem cell
biology have made it feasible to derive large quantities of
cardiomyocytes for disease modeling, drug development, and
regenerative medicine. The discoveries of reprogramming and
transdifferentiation as novel biological processes have signifi-
cantly contributed to this paradigm. This review surveys the
means by which reprogramming and transdifferentiation can be
employed to generate induced pluripotent stem cell-derived
cardiomyocytes (iPSC-CMs) and induced cardiomyocytes (iCMs).
The application of these patient-specific cardiomyocytes for both
in vitro disease modeling and in vivo therapies for various cardio-
vascular diseases will also be discussed. We propose that, with
additional refinement, human disease-specific cardiomyocytes
will allow us to significantly advance the understanding of
cardiovascular disease mechanisms and accelerate the develop-
ment of novel therapeutic options.
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Introduction
Despite advances in medical therapy, cardiovascular disease (CVD)
remains a leading cause of morbidity and mortality worldwide.
Concerted efforts in fundamental and translational research are
required to provide novel diagnostic tools and effective therapeutic
approaches for CVD. Mechanistic modeling of CVD as well as
preclinical validation of therapeutic strategies will assist in the
development of next-generation medical therapies that incorporate
recent discoveries in stem cell biology.
Human induced pluripotent stem cell-derived
cardiomyocytes as a novel platform
Although animal models have provided indispensable insights into
systemic whole-organ function in vivo as well as in vitro disease
mechanisms (Fiedler et al, 2014; Houser et al, 2012; Duncker et al,
2015), not all findings from research on rodent cardiomyocytes can
be translated to human cardiomyocytes at the cellular and mole-
cular levels. Human cardiomyocytes, on the other hand, are a
limited resource and cannot be indefinitely maintained in culture.
These facts emphasize the need for novel human cellular and physi-
ological models of CVD. Over the past decade, rapid technological
advances have combined medical and basic sciences in the develop-
ment and evaluation of novel therapeutics. One exciting advance
has been the ability to generate patient-specific induced pluripotent
stem cells (iPSCs; Takahashi & Yamanaka, 2006). Human iPSCs
resemble human embryonic stem cells (ESCs), the “gold standard”
for pluripotency, in their biological properties but without the
ethical and political concerns associated with the use of human
embryos. Therefore, iPSCs and their differentiated cardiomyocytes
(iPSC-CMs) are considered a viable new and ethically less problem-
atic, alternative platform for studying mechanisms of CVD and eval-
uating novel therapeutic avenues (Fig 1). In addition, human iPSCs
present the unprecedented opportunity to study disease-specific
differences in a patient-specific manner, taking into account indivi-
dual drug responses within a patient population. The validity of this
approach is exemplified by the successful application of human
iPSCs to model LEOPARD syndrome (Carvajal-Vergara et al, 2010),
Timothy syndrome (Yazawa et al, 2011), long QT syndrome
(Moretti et al, 2010; Itzhaki et al, 2011; Wang et al, 2014),
arrhythmogenic right ventricular dysplasia (ARVD) (Kim et al, 2013;
Asimaki et al, 2014), familial dilated cardiomyopathy (DCM; Sun
et al, 2012), familial hypertrophic cardiomyopathy (HCM; Lan et al,
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2013), viral cardiomyopathy (Sharma et al, 2014) and aldehyde
dehydrogenase 2 genetic polymorphism (Ebert et al, 2014). These
accomplishments demonstrate the tremendous power and versatility
of iPSC-CMs in helping to develop novel therapeutic approaches for
CVD and paving innovative avenues for precision medicine in the
future.
Reprogramming of somatic cells to iPSCs
The initial proof-of-concept studies on generation of ESC-like cells
were performed using retroviral transduction of mouse fibroblasts
with the transcription factors Oct4, Sox2, Klf4, and c-Myc (Takahashi
& Yamanaka, 2006). These first-generation iPSCs featured unlimited
self-renewal, differentiation into tissues of all germ layers, and the
ability to generate an entire organism. However, these earlier
approaches involved random insertion of reprogramming factors
into the cellular genome, with consequent risk of oncogenic transfor-
mation. Subsequently, newer and safer non-integrating approaches
employing Sendai virus (Ban et al, 2011), adenovirus (Fusaki et al,
2009; Zhou & Freed, 2009), episomal plasmids (Okita et al, 2008; Yu
et al, 2009), minicircle (Jia et al, 2010) or co-MIP (Diecke et al,
2015), mRNA (Warren et al, 2010) or microRNAs (Lin et al, 2011),
and direct protein delivery (Kim et al, 2009) have been developed
(Fig 1). Based on initial observations in mouse ESCs, two states of
pluripotency were defined, an earlier one occurring in normal
embryonal development termed “naı¨ve” versus a “primed” state
(Nichols & Smith, 2009). Naı¨vety is the ground state of pluripotency.
Naı¨ve pluripotent stem cells (PSCs) can be maintained in vitro by
supplying leukocyte inhibitory factor (LIF) combined with inhibition
of MAPK/ERK kinase (MEK) and glycogen synthase kinase 3 (GSK3)
signaling and are characterized by two active X chromosomes in
female lines. Primed PSCs are dependent on fibroblast growth factor 2
(FGF2) signaling and transforming growth factor-b (TGFb) signaling
and display inactivation of one X chromosome (Nichols & Smith,
2009; Hirai et al, 2012). Human ESCs and iPSCs are consi-
dered to share some properties of naı¨ve mouse ESCs, but mainly
resemble primed murine epiblast stem cells (Nichols & Smith, 2009;
De Los Angeles et al, 2012). Naı¨ve human iPSCs can be derived by
reversion of primed iPSCs into a state that resembles naı¨ve mouse
ESCs (Gafni et al, 2013; Theunissen et al, 2014). Currently, it is
unknown whether these naı¨ve human ESCs and iPSCs represent
distinct intermediates in embryonic development. Further research is
required to elucidate whether human naı¨ve iPSCs may be more
amenable to introduction of genomic modifications (Gafni et al,
2013) or may differentiate more efficiently into somatic tissues
(Honda et al, 2013; Rais et al, 2013; Theunissen et al, 2014).
It has been acknowledged that reprogrammed iPSCs can retain
specific DNA methylation profiles associated with their parental
source cell type (Bar-Nur et al, 2011; Kim et al, 2011; Lister et al,
2011). Variations in these signatures also appear to account for intra-
line variability among different clones originating from the same
iPSC line (Kim et al, 2011; Lister et al, 2011). The long-term effect of
epigenetic pattern retention, such as methylation profiles from the
originating somatic cell type, is not yet fully understood. However,
the somatic source cell type is known to affect differentiation effi-
ciency into iPSC-CMs. For example, cardiac progenitor cell-derived
iPSC lines have shown an enhanced ability to differentiate into
cardiomyocytes compared to fibroblast-derived iPSC lines (Sanchez-
Freire et al, 2014). Prolonged propagation of iPSCs through many
passages reduces these effects, suggesting that residual epigenetic
memory is attenuated in the course of long-term culture (Ohi et al,
2011; Sanchez-Freire et al, 2014). These studies demonstrate that
epigenetic memory is a key determinant of iPSC differentiation into
lineages that are distinct from the parental cell type.
Pluripotent reprogramming and transdifferentiation of cells from
one germ layer to another (Ladewig et al, 2013) have altered the
concept of cell fate as determined by unidirectional progression
(Takahashi & Yamanaka, 2006; Ieda et al, 2010; Vierbuchen et al,
2010; Huang et al, 2011) and illustrate the plasticity of differentia-
tion and lineage specification. Epigenetic roadblocks repressing
chromatin in its inactive state occur during iPSC reprogramming
(Kim et al, 2010; Carey et al, 2011; Theunissen & Jaenisch, 2014), and
a similar role for chromatin remodeling complexes also exists during
cardiovascular development (Chang & Bruneau, 2012; Bevilacqua
et al, 2014). Epigenetic modulators can alter DNA methylation and
Glossary
Cell therapy
Transplantation of therapeutic cell populations (e.g., adult stem cells
or PSC-CMs) to ameliorate damage in the infarcted heart and
improve cardiac function
Disease modeling
Understanding the functional and molecular causes of diseases by
recapitulating their respective phenotypes in organisms (e.g., mouse,
zebrafish) or tissue-specific cell models (e.g., human iPSC-CMs)
Drug discovery
Identifying new therapeutics by employing a wide range of scientific
methods and model systems
Genomewide association study (GWAS)
A whole-genome association study that assesses common genetic
variants (e.g., single nucleotide polymorphisms) in defined populations
of individuals
Genome editing
Modifying the DNA of a given genome in specific sites with
genetically engineered nucleases
Investigational new drug (IND) application
Filing admission of research on a new drug, treatment, or patient
population in human subjects with a regulatory agency (e.g., the US
Food and Drug Administration)
Non-integrating reprogramming
De-differentiation of somatic cells to induced pluripotent stem cells
(iPSCs) using reprogramming factors that do not integrate into the
host cell genome
Paracrine mechanisms
Chemical signals secreted from one cell (e.g., growth factors or
chemokines) to induce functional changes in nearby cells
Tissue engineering
A strategy to replace damaged myocardium via generation of
engineered heart muscle (EHM), which is a functional tissue-like
structure constructed in vitro from adult stem cells or PSC derivatives
Transdifferentiation
Direct somatic cell reprogramming from one germ layer of origin to
another
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histone acetylation profiles, thereby opening or repressing chroma-
tin in target gene loci that direct lineage fate. Clearly, epigenetic
checkpoint regulators of development and lineage differentiation
(Takeuchi & Bruneau, 2009; Wang, 2012) are candidates for targeted
modulation during iPSC reprogramming and cardiac differentiation.
In this context, small molecule compounds are a highly promising
resource for further improving the efficiency of cardiovascular
lineage differentiation (Efe et al, 2011).
Cardiac differentiation of iPSCs
Today, efficient differentiation protocols allow the generation of
large quantities of highly enriched cardiomyocyte populations.
These achievements have been made possible by pivotal work
utilizing spontaneous aggregation of iPSCs in suspension as embry-
oid bodies (EBs) in combination with stage-defined growth factors
(Kehat et al, 2001; Mummery et al, 2007; Burrdige et al, 2011;
Kattman et al, 2011). Subsequently, these protocols led to the
establishment of monolayer systems that stimulate the superfamily
of TGFb receptors via growth factors such as activin A and bone
morphogenetic protein 4 (BMP4; Paige et al, 2010; Zhang et al,
2012), resulting in activation and repression of the canonical Wnt
signaling pathway, respectively. Most recently, specific small mole-
cules have been employed to replace growth factors as modulators
of these signaling pathways (Fig 1; Lian et al, 2012).
The relative immaturity of iPSC-CMs remains a challenge
because it limits their use for disease modeling, drug discovery, and
regenerative medicine purposes (Karakikes et al, 2015). Attempts to
bypass this limitation have demonstrated that long-term culture
enhances the appearance of more mature sarcomeric structural
organization in iPSC-CMs (Kamakura et al, 2013). In addition,
external cues such as electrical stimulation and mechanical cyclic
stretching have been reported to aid in obtaining functionally
Somatic cells
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Figure 1. Generation and applications of patient-specific cardiomyocytes.
From isolated patient-specific source cells such as dermal fibroblasts or peripheral blood mononuclear cells (PBMCs), cardiomyocytes can be generated via iPSC
reprogramming and subsequent differentiation to iPSC-CMs, or by transdifferentiation into iCMs. Both strategies employ a set of defined factors that cause drastic
modulatory changes in the cellular epigenome. Disease-specific mutations within iPSCs can be corrected via genome editing approaches and can be employed for studying
disease mechanisms, drug discovery, and regenerative medicine. While in vivo applications of iCMs are already being evaluated, the suitability of iCMs for other purposes such
as disease mechanism and drug development studies remains to be ascertained.
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mature iPSC-CMs (Lieu et al, 2013; Hirt et al, 2014a). Improvements
in iPSC-CM maturation were also achieved via novel 3D culture
methods (Nunes et al, 2013; Rao et al, 2013) and genetic overex-
pression of distinct factors (Fu et al, 2011; Bett et al, 2013; Lieu
et al, 2013), and these approaches are currently subjects of intense
research.
Maturation affects specification of cardiomyocyte subtypes and is
vital for accurate recapitulation of disease phenotypes (Lan et al,
2013), including fundamental functional features such as more
mature ion channel currents, densities, and kinetics (Sartiani et al,
2007; Yang et al, 2014). The early developmental stage produced by
state-of-the-art iPSC-CM differentiation protocols is sufficient for
analysis of certain hereditary channelopathies that cause ventricular
tachyarrhythmias (Sallam et al, 2015). However, depending on the
exact stage of development, there are numerous differences in elec-
trical conduction and coupling as well as the contractile rate and
force, compared to human adult cardiomyocytes (Karakikes et al,
2015). Furthermore, insufficient maturation of iPSC-CMs compared
to adult human cardiomyocytes has also hindered a broader applica-
tion of these cells for primary drug discovery and validation. Never-
theless, their use in exploratory studies and for examination of drug
toxicity is clearly justified.
A related concern regarding iPSC-CM differentiation is the vary-
ing degree of heterogeneity achieved in the generated cardiomyocyte
population. Current iPSC or ESC differentiation strategies yield a
heterogeneous mixture of atrial-like and ventricular-like lineages, as
well as pacemaker-like lineages such as atrioventricular node-like,
sinoatrial node-like, and Purkinje fiber-like cells (Burridge et al,
2012). A deeper understanding of directed lineage differentiation,
followed by its modulation, would facilitate subtype-specific cardiac
differentiation. This can include direct manipulations at the epige-
netic level or by achieving mRNA-based delivery of lineage-specific
factors (Ong et al, 2015).
The most immediate need, however, is to achieve defined culture
conditions and standardized protocols that address the issue of
iPSC-CM maturation. In a broader sense, reproducibility and stan-
dardization throughout the scientific community will be a key to
ensuring comparable datasets, as well as strides toward a broader
applicability of iPSC-CMs for disease modeling and drug develop-
ment. Although still at its infancy, the field has already made signifi-
cant progress toward the defined derivation and propagation of
human iPSCs and iPSC-CMs (Chen et al, 2011; Burridge et al, 2014;
Ribeiro et al, 2015).
Genetic engineering and personalized medicine
To understand the molecular and genetic determinants of CVD,
advanced genome editing techniques are required to study geno-
type/phenotype relationships and to allow for the correction of
patient-specific mutations in human iPSCs (Wang et al, 1995; Chen
et al, 1998; Schwartz et al, 2000; Benson et al, 2003; Fig 1). Initial
pioneering work was performed using zinc-finger nucleases (ZFNs),
a widely used technology for genomic correction that relies on the
fusion of the FokI restriction endonuclease with zinc-finger proteins.
These nucleases induce target site-specific double-stranded breaks,
which stimulate endogenous DNA repair pathways. Due to the
complexity of the required engineering steps, ZFNs have been
largely supplanted by transcription activator-like effector nucleases
(TALENs), and more recently by the clustered regulatory inter-
spaced short palindromic repeats (CRISPRs)/Cas9 nuclease system.
TALENs display enhanced specificity as well as reduced off-target
action compared to ZFNs. Importantly, single-base pair recognition
by TALENs or CRISPRs can correct single nucleotide exchange
mutations (Hockemeyer et al, 2011; Ding et al, 2013; Lin et al,
2014). CRISPRs are the most accessible means to facilitate and opti-
mize genetic engineering. Their specificity and off-target effects are
currently being evaluated, as these nucleases have the potential to
bind and cut sites other than the primary target site (Hendel et al,
2015). Nevertheless, in a relatively short time, CRISPRs have been
demonstrated to be a cost-effective and time-efficient approach for
genomic correction or introduction of site-specific mutations
(Sander & Joung, 2014). Genome-corrected and disease-introduced
isogenic cell lines are particularly valuable, as they share a common
genotype with the exception of the disease-causing mutation,
thereby eliminating confounding effects from genetic heterogeneity.
Genomic modification to directly correct disease-specific point
mutations in vitro is also valuable for exploring drug development
in patient-specific cardiomyocytes. Human iPSC-CMs are currently
being utilized as a system to evaluate novel and existing medica-
tions and to test patient-specific drug responses (Liang et al, 2013;
Navarrete et al, 2013; Wang et al, 2014). For instance, iPSC-CMs
from patients carrying long QT syndrome mutations (e.g., KCNQ1
G269S) and genome-edited iPSC-CMs with these disease-causing
mutations were both shown to display long QT phenotypes (Liang
et al, 2013; Wang et al, 2014). Furthermore, both cell types revealed
comparable disease-specific responses following drug treatment
(e.g., nifedipine) to rescue prolongation of action potential duration
(APD) (Liang et al, 2013; Matsa et al, 2014; Wang et al, 2014).
Overall, these examples illustrate the potential for using genome
editing to generate accurate, reliable, and less expensive in vitro
human models for understanding CVD and for accelerating drug
discovery (Fig 1; Ebert et al, 2012). Moreover, genome editing may
accelerate the future clinical application of integration-free cell-
based gene therapy, including the autologous transplantation of
patient-specific, genome-corrected iPSC-CMs.
The complexity of genotype/phenotype relationships is further
magnified by genetic background variation and variability among
iPSC lines (Table 1). Genome-wide association studies (GWAS) and
subsequent data mining identify signaling pathways governing the
control of disease-relevant targets. Large numbers of critical gene
loci and related mutations have been described by GWAS and linked
to pathogenic phenotypes. Variants occurring in these regions can
influence the regulation of disease-relevant gene expression (Fig 1).
Moreover, late-onset or incomplete penetration of the disease
phenotype can complicate further readout and genotypic correla-
tion. In those cases, response profiling of well-established
compounds and drugs in CVD might provide further insight.
However, the presence of line-to-line and genetic background varia-
tion implies that additional layers of control are required to confirm
genotype/phenotype relationships. Rescue of pathogenic functional
features following genomic correction of the disease-related locus
via TALENs or CRISPRs, the use of isogenic controls, and suffi-
ciently powered studies are means to address these limitations.
Given our ability to introduce specific disease-causing mutations
into both iPSCs and ESCs, it is likely that instead of isolating
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primary cells from affected patients and generating disease-specific
iPSCs and iPSC-CMs, the field will evolve toward standardized
procedures based on introducing mutations of interest into fully
sequenced and characterized reference stem cell lines (iPSCs and/or
ESCs) to assess disease-specific genotypic and phenotypic relation-
ships (Sallam et al, 2015).
Direct conversion to induced cardiomyocytes (iCMs)
There are both advantages and disadvantages in reprogramming of
somatic cells to iPSCs. The intrinsic properties of iPSCs enable the
use of tools such as genome editing to facilitate our understanding
of basic disease mechanisms, as well as to evaluate precision medi-
cine approaches (Wilson & Wu, 2015). Nevertheless, despite metho-
dological advances, the entire process of generating patient-specific
iPSC-CMs still requires several months and presents a potential risk
of teratoma formation for regenerative medicine, given that the
presence of residual pluripotent cells in the final product cannot be
completely excluded (Lee et al, 2013). As a result, other approaches
that eliminate the need for pluripotent stem cell generation are being
explored.
In recent years, proof-of-concept studies have shown that
somatic cells can be directly converted to cardiomyocytes (Fig 1;
Ieda et al, 2010; Efe et al, 2011; Qian et al, 2012). Transgenic
expression of three cardiac-specific transcription factors (Gata4,
Mef2c, and Tbx5) resulted in the transdifferentiation of murine
fibroblasts into contracting cardiomyocytes referred to as induced
cardiomyocytes (iCMs; Ieda et al, 2010). Intriguingly, the same
outcome has been observed during an epigenetic activation phase
in the early stage of reprogramming. This approach employed
ectopic expression of transcription factors together with growth
factors (Efe et al, 2011), demonstrating elegantly how cellular
complexity can be harnessed for the understanding of specific
molecular processes. Other reports have shown that direct repro-
gramming of somatic cells to iCMs is also feasible using various
small molecules and miRNAs (Jayawardena et al, 2012, 2014;
Protze et al, 2012).
Recently, direct reprogramming of human fibroblasts has also
been achieved (Islas et al, 2012). Several studies showed that the
murine direct reprogramming factors Gata4, Mef2c, and Tbx5
(GMT), or GMT plus Hand2 (GHMT), were insufficient to transform
human fibroblasts into iCMs (Nam et al, 2013; Wada et al, 2013),
indicating that the differences between mouse and human cardio-
vascular development need to be considered for optimal transdiffer-
entiation to human iCMs. A combination of Gata4, Hand2, Tbx5,
myocardin, miR-1, and miR-133 could convert human adult dermal
fibroblasts into induced cardiomyocyte-like cells (iCMLs). The trans-
duction of these factors promoted substantial cardiac troponin T
expression in at least 9% of the source population (Nam et al,
2013). Shortly afterward, introduction of GMT plus Mesp1 and
myocardin (GMTMM) was also shown to successfully convert
human fibroblasts to iCMLs (Wada et al, 2013). Since then, alterna-
tive approaches have succeeded in generating human iCMs with
gene expression profiles and functional characteristics similar to
those detected in ESC-CMs (Fu et al, 2013).
Current limitations and the routes toward
therapeutic application
Direct reprogramming as an alternative to deriving human iPSCs
offers the advantage of a 2-week timeline, compared to 2–3 months
(Table 1). However, current methods for producing iCMs suffer from
low efficiencies compared to iPSC differentiation (Chen et al, 2012).
Depending on the combination of transcription factors used, human
fibroblasts convert into iCMs with different efficiencies, ranging from
5% (GMTMM; Ieda et al, 2010) to 13% (Gata4, Hand2, Tbx5,
Myocd, miRNA 1, and miRNA 133; Fu et al, 2013) based on troponin
T-positive cells. Recently, polycistronic vectors have been used to
express the GMT factors in appropriate stoichiometry as a single
mRNA, which has significantly increased the efficiency of mouse
Table 1. Challenges and opportunities of de novo generated cardiomyocytes for disease modeling, drug discovery, and regenerative therapies.
Parameters
CM generation strategy
iPSC reprogramming and differentiation Direct reprogramming Human ESC differentiation
Mechanism De-differentiation to iPSCs followed by
specific differentiation to CMs
Transdifferentiation Specific differentiation to CMs
Timeline 2–3 months 2–3 weeks 2–3 weeks
Efficiencies (% cTnT) 90–95% 9–13% 90–95%
Genome editing, isogenic controls Yes No Yes
Genetic variation Yes Not yet determined No
Disease modeling, drug development Yes Current efficiencies too low Yes
Patient-specific assessment of
phenotypes and drug function
Yes Currently undergoing
investigation
No
In vivo preclinical evaluation
of regenerative therapies
Yes Yes Yes
Clinical safety and efficacy Not yet determined Not yet determined Currently undergoing investigation
Ethical concerns No No Yes
EMBO Molecular Medicine Vol 7 | No 9 | 2015 ª 2015 The Authors
EMBO Molecular Medicine Stem cells in cardiovascular development and therapy Antje D Ebert et al
1094
fibroblast conversion in vitro up to 25% (Inagawa et al, 2012; Wang
et al, 2015). However, these results remain to be replicated in
human fibroblasts. In addition, successful generation of pure iCM
populations has not yet been reported. Indeed, direct transdifferenti-
ation has so far generated heterogeneous populations of cardiomyo-
cyte-like cells representing various early developmental stages,
which rarely display spontaneous beating and produce only sporadic
action potentials (Fu et al, 2013). In general, the overall low transdif-
ferentiation efficiency of iCMs into bona fide cardiomyocytes is the
main obstacle for the required scale-up of cell production.
Like iPSC-CMs, iCMs must undergo additional maturation before
they can serve as true models of adult cardiomyocytes (Bedada et al,
2014; Yang et al, 2014; Jayawardena et al, 2015). The accurate deter-
mination of the differences between these cell types requires the direct
comparison of iCMs with both iPSC-CMs and human adult cardiomyo-
cytes (Protze et al, 2012; Wada et al, 2013). While similarity of iCMs
to ESC-CMs (Fu et al, 2013) has been reported, including subtype
specification as a feature of mature cardiomyocyte populations (Nam
et al, 2014), other studies have indicated that human iCMs generated
in vitro may be even more immature than human iPSC-CMs (Wada
et al, 2013). These findings imply that iCMs may reflect the early fetal
stage of embryonic cardiomyocytes, and hence, co-stimulation with
appropriate factors may drive maturation of iCMs in vitro. Potential
approaches include mechanical stimuli or secreted molecules related
to the normal myocardial environment, such as cardiac matrix scaf-
folds and secreted paracrine factors. Exposure to stretching forces is
also thought to accelerate iCM generation and maturation (Qian &
Srivastava, 2013). Thus, current limitations of efficient generation and
maturation of iCMs in vitro may be addressed by advancing in vivo
reprogramming instead.
miRNAs have been demonstrated to be sufficient for direct repro-
gramming to iCMs without addition of any transcription factors
(Jayawardena et al, 2012). Current research has thus far focused on
their use as powerful drivers of lineage fates (Cordes & Srivastava,
2009; Boon & Dimmeler, 2015). It is likely that miRNAs promote
cardiac induction by suppressing fibroblast signatures, as for exam-
ple, miRNA133-mediated inhibition of Snai1-controlled expression
pathways (Muraoka et al, 2014). Therefore, an optimized cocktail
to promote the generation of more mature iCMs may include
specific miRNAs, as well as specific chemical epigenetic modulators.
Should such strategies result in higher efficiency of iCM reprogram-
ming and improved maturation, safety and efficacy would need to
be assessed in studies similar to those required for human iPSC-
CMs. For now, a direct comparison of iCMs with iPSC-CMs regard-
ing their functional properties remains to be performed. Initial
comparative evaluations should focus on functional parameters
such as electrophysiology and calcium handling, and also gene and
protein expression patterns. Subsequently, the beneficial effects of
either cell type on improving cardiac function in preclinical models
of CVD will need to be demonstrated. Likewise, the long-term stabil-
ity of iPSC-CM and iCM phenotypes must be assessed to address
safety and efficacy issues.
Heart disease and novel therapeutic approaches
Two of the main classes of genetically inherited heart diseases
include channelopathies and cardiomyopathies. Channelopathies or
arrhythmic cardiac disorders are caused by mutations in genes
encoding ion channels, such as SCN5A that encodes the cardiac
Na+ channel a-subunit. The functional characteristics include volt-
age gating and/or protein trafficking defects, which can result in
gain or loss of function in the Na+ channel and subsequent ventri-
cular arrhythmias, leading to diseases such as long QT syndromes
(Lehnart et al, 2007). By contrast, cardiomyopathies, or defects in
heart muscle contraction, are most frequently caused by mutations
in cytoskeletal or contractile proteins (McNally et al, 2013). The
relevant pathogenic features are transversely isotropic, consisting of
irreversible ventricular dilatation and systolic dysfunction that cause
severely impaired ventricular contraction. Both channelopathies and
cardiomyopathies can also be caused by non-hereditary, acquired
determinants such as chronic or acute ischemia (Fig 2), and by
drugs or autoimmune events (Kass, 2005).
Human models of iPSC-CMs have successfully recapitulated
numerous genetically determined CVD, including long QT, DCM,
HCM, and ARVD (Moretti et al, 2010; Yazawa et al, 2011; Davis
et al, 2012; Sun et al, 2012; Caspi et al, 2013; Lan et al, 2013).
These studies have demonstrated that iPSC-CMs display phenotypic
disease features such as abnormal sarcomere alignment and stria-
tion, as well as critical functional properties such as propagation of
calcium transients in amplitude, time to peak, duration, and decay
(Moretti et al, 2010; Yazawa et al, 2011; Davis et al, 2012; Sun
et al, 2012; Caspi et al, 2013; Lan et al, 2013). Importantly, iPSC-
CMs allow for quantitative analysis of electrical properties regarding
the action potential’s upstroke velocity, time to peak, and duration.
For example, abnormally prolonged APD and decreased repolariza-
tion velocity are detected in long QT patient-derived iPSC-CMs
(Yazawa et al, 2011; Table 1).
Pathogenesis of myocardial infarction and regeneration of
the heart
The early phase during and after an infarction is characterized by
inflammatory, necrotic, and apoptotic cellular responses. The ensu-
ing late or chronic phase includes an expansion of the infarcted
region in the myocardial wall, recruitment of myeloid cells, tissue
necrosis, and degradation of the extracellular matrix (ECM). Subse-
quent neoangiogenesis and remodeling of the left ventricle (LV)
entails scar formation, hypertrophic expansion of cardiomyocytes,
and fibrosis. The resulting dilation of the LV is accompanied by
increased frequency of arrhythmias, myocardial dysfunction, and
eventually heart failure. Conventional therapy of fibrosis and LV
dilatation by angiotensin converting enzyme (ACE) inhibitors and
angiotensin II receptor blockers (ARBs) partially counteracts these
deleterious consequences and attenuates adverse remodeling (Dorn,
2009). Nevertheless, viable cardiomyocytes are lost to a large extent
in the area of myocardial infarction (MI).
Recent studies suggest that the heart is capable of limited endog-
enous regeneration (Bergmann et al, 2009; Parmacek & Epstein,
2009; Porrello et al, 2011; van Berlo et al, 2014). While proliferation
of the heart may occur to a minor extent throughout the lifetime of
an organism, active cell division of cardiomyocytes is limited to the
embryonic stage (Bergmann et al, 2009; Porrello et al, 2011). A
different source of endogenous heart regeneration is the resident
adult stem cell population, known as cardiac progenitor cells
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(CPCs), reported to be capable of differentiating and proliferating to
replenish apoptotic cardiomyocytes (Fig 2; Dimmeler et al, 2005;
Leri et al, 2011). The full regenerative capacities of these cells
remain controversial and are discussed in detail elsewhere (Laflamme
& Murry, 2011; Anversa et al, 2013; Maillet et al, 2013, van Berlo et
al, 2014). Overall, the endogenous proliferation and repair abilities
of the heart are not sufficient to allow the repopulation of damaged
myocardial areas with new cardiomyocytes following MI.
Stem cell-derived cardiomyocytes for heart
disease therapy
Previous clinical trials have employed various adult stem cell and
progenitor cell populations to test their efficacy for therapeutic
applications (Fig 2; Assmus et al, 2002; Schachinger et al, 2004;
Losordo et al, 2007; Chugh et al, 2012; Hare et al, 2012; Makkar
et al, 2012; Traverse et al, 2012; Vrtovec et al, 2013; Karantalis
et al, 2014). Safety and feasibility of these cells have been demon-
strated in these scenarios, and extensive efforts have been spent
on exploring the therapeutic potential of these cells. Overall, the
results have shown varying degrees of clinical benefit in MI patients
(Sanganalmath & Bolli, 2013). Currently, additional approaches are
being explored, including transplantation of new cell types (e.g.,
human ESC-cardiac progenitor cells (Menasche et al, 2015) or iPSC-
CMs), or application of alternative delivery approaches such as
implantation of in vitro constructed cell sheets of engineered heart
muscles (EHMs) (Fig 2; Zimmermann, 2013; Emmert et al, 2014; Hirt
et al, 2014b). One mechanism by which cell therapy (e.g., ESC-CMs
or iPSC-CMs) may improve outcomes is via engraftment of trans-
planted cells within the host environment, which in theory would
lead to the replacement of damaged cardiomyocytes and fibrotic
tissue, and restore structural support of the ventricular walls. Exten-
sive studies have focused on grafts within the non-infarcted versus
infarcted myocardium in small and large animal models (Laflamme
et al, 2007; van Laake et al, 2008). Human grafts express cardiac
markers and displayed sarcomere alignment as well as integration
with the host’s vasculature. In this context, coupling of transplanted
cardiomyocytes with the host myocardium is considered a vital
factor contributing to improved cardiac function. Stem cell-derived
cardiomyocytes couple to a limited extent with the host myocardial
cells in small animal models (Kehat et al, 2004). Large animal
models such as pigs and non-human primates are more valuable
due to the greater resemblance of their heart rates with the beating
frequency of transplanted cardiomyocytes (Chong et al, 2014).
However, to a large extent, functional improvement in left ventri-
cular ejection fraction (LVEF) in some of these transplantation models
has been suggested to result through the release of paracrine factors
Gata4
Mef2c
Tbx5
Hand2
Mesp1
Myocardin
miR-1
miR-133
iCMs
REGENERATED 
MYOCARDIUM
IN SITU
REPROGRAMMING
Adult stem and 
progenitor cells
EHMs
iPSC-CMs
Figure 2. Cell therapy and tissue engineering approaches for cardiovascular disease therapy.
Heart failure due to ischemic heart disease or genetic disorders remains a major healthcare burden. Potential novel treatment options include transplantation of iPSC-CMs or
ESC-CMs, as well as direct in vivo reprogramming of cardiac fibroblasts in the scar region to iCMs. The regenerative capacity of adult stem and progenitor cell populations is
also being evaluated. Tissue engineering is a new method that aims to re-muscularize damaged myocardium via transplantation of in vitro engineered heart muscle made
from iPSC-CMs or ESC-CMs.
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(Gnecchi et al, 2005; Gu et al, 2012; Huber et al, 2013). Trans-
planted cells may secrete signaling molecules that exert beneficial
functions directly or by altering gene expression patterns in the
surrounding myocardium. Such paracrine mechanisms have been
frequently proposed to contribute to the recovery of cardiac function
(Gnecchi et al, 2005). Well-studied factors such as vascular endo-
thelial growth factor (VEFG; Zangi et al, 2013) and thymosin b-4
(TB4; Smart et al, 2010, 2011) have been selectively characterized
in murine infarct models for their capacity to mediate cardiac repair.
Recently, targeted approaches to identify specific paracrine factors
revealed novel paracrine-acting proteins that could improve tissue
and heart function following MI (Korf-Klingebiel et al, 2015). In the
future, cell-based therapies may benefit from these findings by inte-
grating delivery of specific factors into the transplanted therapeutic
composite. Moreover, complementing the cell mixture with iPSC-
derived endothelial cells may lead to beneficial effects from the
developed vasculature (Ye et al, 2014). Together, these synergistic
approaches may help promote engraftment, vascularization, and
structural integrity of the ventricular walls.
To date, three fundamental issues have slowed the clinical
translation of iPSC-CMs or ESC-CMs: the risk of tumor formation,
poor survival of transplanted cells, and the need for immunosup-
pression for allogeneic ESC and iPSC derivatives. The first obstacle
includes both tumors potentially arising from random insertion of
integrating reprogramming vectors, and the risk of teratomas aris-
ing from residual undifferentiated stem cells (Lee et al, 2009, 2013).
Novel non-integrating iPSC reprogramming strategies may decrease
risk, while increasing the efficiency of differentiation or the purity
of the final cell product could minimize teratoma risk (Tang et al,
2011). The second major obstacle is acute donor cell death due to
hypoxia, anoikis, and inflammation, as well as lack of blood supply
(Li et al, 2009a,b; Liu et al, 2012; Nguyen et al, 2014). Hence, the
majority of current cardiac cell therapies (both basic and clinical)
appear to achieve beneficial effects without long-term persistence of
the cells, presumably through the release of paracrine factors to the
host heart prior to transplanted cell loss as described earlier
(Gnecchi et al, 2005). Relating practical issues include generation of
sufficient infarct sizes in the chosen species to induce a measure-
able decline in heart function without killing the animal. In some
cases (e.g., guinea pigs and dogs), the collateral circulation is so
high that meaningful infarcts cannot be generated by coronary
artery ligation (Verdouw et al, 1998). These concerns are critical
for investigational new drug (IND)-enabling large animal studies
in the evaluation of the safety and efficacy of stem cell-derived
therapies.
The third obstacle toward clinical applications of iPSC-CMs or
ESC-CMs is the need for effective immunosuppression to reduce
rejection in allogeneic settings, which can be daunting (Pearl et al,
2011, 2012). The use of more sophisticated immunosuppressive or
tolerance induction strategies (Huber et al, 2013) as well as combi-
nations of iPSC-CMs with potentially immunotolerant iPSC-derived
mesenchymal stem cells (iPSC-MSCs) is being investigated (Lian
et al, 2010). An alternative approach is the creation of human
leukocyte antigen (immunosuppression HLA)-matched cell banks
from healthy donors that contain selected iPSC lines with maxi-
mized HLA genotype overlap, which may minimize the need for
immunosuppression (Taylor et al, 2012; Neofytou et al, 2015).
However, an important caveat to this approach was recently found
in the heterogeneity of human mitochondria and, specifically,
mismatched mitochondrial antigens, which by themselves can trigger
rejection in transplant models (Deuse et al, 2015).
In vivo applications of iCMs
Direct application of iCM reprogramming in vivo may promote
patient-specific precision therapy by reducing the accompanying
costs and efforts, which are considerable with in vitro generation of
patient-specific iPSC-CMs. Induced cardiac regeneration in vivo via
iCMs might circumvent current unresolved issues in iPSC-CM ther-
apy, such as poor survival and engraftment of transplanted cells.
However, the degree of functional cardiac improvement resulting
from in situ transdifferentiated iCMs is unknown, as is the extent of
their coupling and integration within the host myocardium
(Table 1). Safety and potential off-target effects of iCM reprogram-
ming cocktails have yet to be studied in detail, and the conse-
quences of in vivo transfection of “off-target” cells such as
endothelial, smooth muscle, or cardiac cells in the heart are also
unknown and can be problematic. Finally, another consideration is
the reproducibility of iCM generation using viral delivery
approaches, which can lead to host immune response, as compared
to non-viral or small molecule approaches, which may have poor
pharmacokinetics in vivo (Chen et al, 2012). In summary, many
challenges remain to be resolved before therapeutic application of
iCMs in the clinic can even begin.
Tissue engineering
Currently, heart transplantation is the only viable therapy for
end-stage heart failure but remains problematic due to a chronic
shortage of organ supply, as well as the persistent risk of immune
rejection. An alternative strategy for regeneration of damaged
myocardium is to exploit therapeutic cells such as iPSC-CMs for the
construction of 3D structures in vitro, and subsequent transplanta-
tion of these engineered cardiac patches (Caspi et al, 2007; Tulloch
et al, 2011; Kawamura et al, 2012). This technology is known as
“tissue engineering” or generation of engineered heart muscle
(EHM). Transplantation of a tissue patch/EHM ensures increased
precision of delivery onto damaged myocardial areas, as well as full
retention of transplanted material. EHM transplants may also allow
direct substitution of scar tissue in the infarcted area with new,
healthy cardiac muscle, minimizing long-term damage resulting
from scar growth and ultimately reducing adverse remodeling and
improving cardiac function (Fig 2). Moreover, it is expected that 3D
cardiac tissues may mature into more adult-like structures compared
to single cardiomyocytes, which is considered essential for optimal
integration into the host environment. Several key features of matu-
ration, such as alignment, orientation, and binucleation of cardio-
myocytes (particularly their sarcomeric structural organization),
were found to be improved in engineered tissues (Zimmermann
et al, 2002; Tiburcy et al, 2011; Zhang et al, 2013). The beneficial
outcomes of tissue engineering-based therapy have been extensively
demonstrated in small animal models (Naito et al, 2006; Zimmer-
mann et al, 2006; Sekine et al, 2008; Tulloch et al, 2011) and are
currently being tested in large animal models. Eventually, EHMs
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may facilitate patient-specific organ transplantation via in vitro
generation of partial or whole-organ structures.
Significant potential problems, such as poor survival of trans-
planted EHMs and their problematic integration into the host
myocardium, need to be resolved before human trials can
commence. A recent study using mouse cardiac sliced tissue as a
benchmark to validate and model tissue-engineered patches showed
poor survival with > 400 lm thickness (Riegler et al, 2014). Detailed
understanding of the complex molecular mechanisms that determine
the engraftment of transplanted EHMs within the host will lead to
better strategies to address these issues. Possible solutions include
co-delivery of supporting scaffold matrices, pro-survival cocktails,
and stimulation of host myocardium via specific chemical molecules.
Standardization of protocols for EHM generation, performance, and
maturation will be a crucial step before moving forward to clinical
trials. The substantial progress made during the past decade holds
promise for a future clinical translation of EHM technology (Tee
et al, 2012; Sekine et al, 2013; Ye et al, 2013; Hirt et al, 2014b).
Conclusions
Pluripotent stem cell-derived cardiomyocytes, induced cardiomyo-
cytes, and engineered heart muscle present exciting new opportuni-
ties for the development of novel CVD treatments. While iCM
production is currently being optimized, iPSC-CMs provide a state-
of-the-art patient-specific model system to study disease mecha-
nisms and develop new drugs. Future studies will have to ascertain
whether ESC-CM-, iPSC-CM-, iCM-, or EHM-based transplantation
can achieve sustained improvement of cardiac function. These
synergistic, multidisciplinary approaches should improve under-
standing of the mechanisms governing cardiovascular health and
disease at the molecular, cellular, and organ levels. Transformation
of this knowledge into therapeutic strategies is the key to achieve
the full potential of regenerative medicine and open a new era of
advances in cardiovascular therapy.
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